{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T21:52:56Z","timestamp":1766181176092,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.oret.2018.11.003","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T10:42:48Z","timestamp":1542278568000},"page":"220-229","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy"],"prefix":"10.1016","volume":"3","author":[{"given":"Kelvin Yi","family":"Chong Teo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Squirrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5766-2193","authenticated-orcid":false,"given":"Gayatri","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3572-6760","authenticated-orcid":false,"given":"Amy","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5431-4991","authenticated-orcid":false,"given":"Daniel","family":"Barthelmes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chui Ming","family":"Gemmy Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Gillies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9827","key":"10.1016\/j.oret.2018.11.003_bib1","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(12)60282-7","article-title":"Age-related macular degeneration","volume":"379","author":"Lim","year":"2012","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.oret.2018.11.003_bib2","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","article-title":"Age-related macular degeneration is the leading cause of blindness","volume":"291","author":"Bressler","year":"2004","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.oret.2018.11.003_bib3","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00006982-199010010-00001","article-title":"Idiopathic polypoidal choroidal vasculopathy (IPCV)","volume":"10","author":"Yannuzzi","year":"1990","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.oret.2018.11.003_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1136\/bjo.84.5.479","article-title":"Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments","volume":"84","author":"Ahuja","year":"2000","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oret.2018.11.003_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/eye.2009.214","article-title":"Haemorrhagic pigment epithelial detachment as a predictive feature of polypoidal choroidal vasculopathy in a Chinese population","volume":"24","author":"Cackett","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.oret.2018.11.003_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1586\/eop.13.3","article-title":"Genetic risk, ethnic variations and pharmacogenetic biomarkers in AMD and polypoidal choroidal vasculopathy","volume":"8","author":"Kuo","year":"2014","journal-title":"Exp Rev Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.preteyeres.2009.10.001","article-title":"Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease?","volume":"29","author":"Laude","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/APO.0b013e31827ff5bc","article-title":"Asian age-related macular degeneration: current concepts and gaps in knowledge","volume":"2","author":"Lim","year":"2013","journal-title":"Asia-Pac J Ophthalmol (Phila)"},{"issue":"5","key":"10.1016\/j.oret.2018.11.003_bib10","first-page":"782","article-title":"Polypoidal choroidal vasculopathy in Asians","volume":"4","author":"Wong","year":"2015","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.oret.2018.11.003_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2016.04.002","article-title":"Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians","volume":"53","author":"Wong","year":"2016","journal-title":"Prog Retin Eye Res"},{"issue":"317","key":"10.1016\/j.oret.2018.11.003_bib12","first-page":"39","article-title":"Polypoidal choroidal vasculopathy, diagnosis and management","author":"Coppens","year":"2011","journal-title":"Bull Soc Belge Ophtalmol"},{"issue":"10","key":"10.1016\/j.oret.2018.11.003_bib13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1136\/bjophthalmol-2016-310074","article-title":"Polypoidal choroidal vasculopathy: a common type of neovascular age-related macular degeneration in Caucasians","volume":"101","author":"Yadav","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.oret.2018.11.003_bib14","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1097\/IAE.0b013e31820d3f3f","article-title":"Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy","volume":"31","author":"Lai","year":"2011","journal-title":"Retina"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/bjo.2007.122283","article-title":"Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy","volume":"92","author":"Gomi","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.oret.2018.11.003_bib16","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajo.2013.05.038","article-title":"Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy","volume":"156","author":"Kang","year":"2013","journal-title":"Am J Ophthalmol"},{"issue":"23","key":"10.1016\/j.oret.2018.11.003_bib17","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMc1107895","article-title":"Ranibizumab and bevacizumab for AMD","volume":"365","author":"Cheung","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.oret.2018.11.003_bib18","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamaophthalmol.2017.4030","article-title":"Efficacy and safety of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: a randomized clinical trial","volume":"135","author":"Koh","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.oret.2018.11.003_bib19","first-page":"93","article-title":"[Assessing aggressive behaviour at the psychiatric emergency service with a checklist: a replication study]","volume":"55","author":"Penterman","year":"2013","journal-title":"Tijdschr Psychiatr"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/IAE.0b013e318296b271","article-title":"Efficient capture of high-quality data on outcomes of treatment for macular diseases: the Fight Retinal Blindness! Project","volume":"34","author":"Gillies","year":"2014","journal-title":"Retina"},{"issue":"9596","key":"10.1016\/j.oret.2018.11.003_bib21","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.oret.2018.11.003_bib22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2147\/OPTH.S54578","article-title":"One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy","volume":"8","author":"Sakurai","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.oret.2018.11.003_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1755-3768.2009.01841.x","article-title":"Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study","volume":"90","author":"Lim","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"10.1016\/j.oret.2018.11.003_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000354546","article-title":"Two-year outcome after combination therapy for polypoidal choroidal vasculopathy: comparison with photodynamic monotherapy and anti-vascular endothelial growth factor monotherapy","volume":"231","author":"Kang","year":"2014","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.oret.2018.11.003_bib25","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000329466","article-title":"One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy","volume":"226","author":"Song","year":"2011","journal-title":"Ophthalmologica"},{"issue":"9","key":"10.1016\/j.oret.2018.11.003_bib26","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ophtha.2015.05.010","article-title":"Long-term outcomes of treatment of neovascular age-related macular degeneration: data from an observational study","volume":"122","author":"Gillies","year":"2015","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.oret.2018.11.003_bib27","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity","volume":"121","author":"Writing Committee for the UKA-RMDEMRUG","year":"2014","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.oret.2018.11.003_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0110667","article-title":"Combined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.oret.2018.11.003_bib29","first-page":"1056","article-title":"Ranibizumab alone or in combination with photodynamic therapy vs photodynamic therapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis","volume":"8","author":"Tang","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oret.2018.11.003_bib30","first-page":"527","article-title":"Anti-VEGF therapy for neovascular AMD and polypoidal choroidal vasculopathy","volume":"6","author":"Cheung","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"10.1016\/j.oret.2018.11.003_bib31","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2017.11.019","article-title":"Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management","volume":"125","author":"Cheung","year":"2018","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.oret.2018.11.003_bib32","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1097\/IAE.0000000000000526","article-title":"Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study","volume":"35","author":"Gomi","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.oret.2018.11.003_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s10384-007-0452-3","article-title":"Role of photodynamic therapy in polypoidal choroidal vasculopathy","volume":"51","author":"Akaza","year":"2007","journal-title":"Jpn J Ophthalmol"},{"issue":"11","key":"10.1016\/j.oret.2018.11.003_bib34","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1097\/IAE.0000000000000236","article-title":"Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab","volume":"34","author":"Saito","year":"2014","journal-title":"Retina"},{"issue":"12","key":"10.1016\/j.oret.2018.11.003_bib35","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1167\/iovs.14-14610","article-title":"Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability","volume":"55","author":"Hata","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2018.11.003_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2016.02.019","article-title":"Intravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathy","volume":"165","author":"Cho","year":"2016","journal-title":"Am J Ophthalmol"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018303142?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653018303142?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T09:25:49Z","timestamp":1762853149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653018303142"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S2468653018303142"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2018.11.003","relation":{},"ISSN":["2468-6530"],"issn-type":[{"type":"print","value":"2468-6530"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Multicountry Comparison of Real-World Management and Outcomes of Polypoidal Choroidal Vasculopathy","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2018.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}